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ceived complaints about its dosage form because the
tablets were too large and a large number of tablets were
required (27.2%). 17.7% of patient who were taking lan-
thanum carbonate did not like the chewable tablets. Con-
clusion: patients who were taking binders that they did
not like had worse serum P levels and were prescribed
higher doses of binders. Knowing patients’ preferences
about the drugs prescribed may be a key factor in achiev-
ing adequate adherence to treatment.
Key words: Phosphate binders. Preferences. Adherence to
treatment. Hemodialysis
Captores del fósforo: preferencias de los pacientes en he-
modiálisis y su repercusión sobre el cumplimiento del tra-
tamiento y el control del fósforo
RESUMEN
Introducción: En la actualidad disponemos de un amplio
abanico de captores del fósforo (CF), pero sabemos poco
acerca de las preferencias de los pacientes y de su repercu-
sión sobre el cumplimiento del tratamiento y el control de
los niveles de fósforo. Objetivo: Estudiar las preferencias y
creencias de los pacientes respecto a los CF, y su influencia
sobre el cumplimiento del tratamiento y el control de los
niveles de fósforo. Pacientes y métodos: Estudio observacio-
nal transversal. Se incluyeron 121 pacientes que respondie-
ron un cuestionario genérico de cumplimiento del trata-
miento (SMAQ) y a un cuestionario específico sobre
cumplimiento del tratamiento con CF, tipo de CF preferido
y razones de dicha preferencia. Todos los pacientes entrevis-
tados habían probado dos o tres CF. Las consecuencias de la
falta de cumplimiento del tratamiento con CF se estimaron
indirectamente analizando los valores promedio de fósforo
sérico. Resultados: El 40% de los pacientes era incumplidor
según el cuestionario SMAQ; se encontró una asociación es-
tadísticamente significativa entre la falta de cumplimiento
ABSTRACT
Introduction: Non-adherence to phosphate binding (PB)
medication may play a role in the difficulty in achieving the
targets for phosphorus. We have a wide armamentarium
of PB but preferences of patients are poorly understood.
Objective: to study the patients’ preferences and beliefs re-
garding PB and their influence on adherence and serum
phosphate. Methods: A cross-sectional cohort study was
performed. A total of 121 hemodialysis patients answered
a specific questionnaire in which they were questioned
about adherence, the type of PB they preferred and the
reasons for their choice. All patients questioned tasted two
or three PB. The consequence of non-adherence to PB was
estimated indirectly by determination of serum phospho-
rus. Results: Specific noncompliance with PB medication
was recognized by 21.4% of patients. Patients non-adher-
ent specifically to PB were more likely to have P levels >5.5
mg/dl (χ2: 4.7; 95% CI 1.07-6.5; P = 0.03). Paradoxically, pa-
tients non-adherent showed greater knowledge of the use
(χ2: 17.3; 95% CI -2.2-10.1; P <0.0001) and importance of
the drug (χ2: 10.4; 95% CI -1.5-6.6; P = 0.001). The percent-
age of patients prescribed binders they did not like was
54.5%. Patients who were taking PB they did not like had
a greater risk of having P levels >5.5 mg/dl) (χ2: 13.3; 95%
CI -1.1-1.5; P = 0.0001). Calcium acetate was the prefered
PB in 47.1% of patients, lanthanum carbonate in 40%,
sevelamer in 20.6% and aluminum hydroxide in 19.4%.
The reasons claimed by patients for their negative ratings
of PB were the type of dosage form, the taste, the num-
ber of tablets and gastric intolerance. Gastric intolerance
and bad taste were more frequent in aluminum hydroxide
patients (19.4% and 22.2%, respectively). Sevelamer re-
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en general y no alcanzar el objetivo de fósforo sérico pro-
medio <5,5 mg/dl (OR = 4,8; IC 95%, 1,0-6,6; P = 0,02). El
21,4% de los pacientes reconocía un incumplimiento espe-
cífico para los CF; estos pacientes presentaban una mayor
probabilidad de tener cifras medias de fósforo >5,5 mg/dl
(OR = 4,7; IC 95%, 1,1-6,5; P = 0,03). Un 43,8% de los pacien-
tes no refirió tener preferencias entre los diferentes tipos
de CF; para el resto de pacientes, el CF preferido fue Royen®,
seguido de Fosrenol®, Renagel® y Pepsamar®. Las razones ex-
presadas para el desagrado con el Renagel® fueron las si-
guientes: incomodidad en la toma por su gran tamaño
(28,8%), necesidad de tomar muchos comprimidos y gran
consumo de agua (57,7%) e intolerancia gástrica (13,3%).
En el caso del Fosrenol®: incómodo de tomar (72,7%) e in-
tolerancia gástrica (27,2%); para el Pepsamar®: mal sabor
(54,5%) e intolerancia gástrica (45,4%). Sólo al 9,4% no le
gustaba el Royen®. Al analizar los conocimientos de los pa-
cientes respecto a la utilidad de los CF, un 42% sabía que
servían para controlar el fósforo; un 52% no lo sabía y
un 6% tenía ideas equivocadas. En cuanto a su importancia:
un 47% no conocía por qué son importantes; un 2% tenía
ideas erróneas; un 9% creía que era beneficioso para la sa-
lud; un 11% creía que era bueno «porque lo dice el medi-
co»; un 26% porque controla el fósforo y un 5% lo relacio-
naba con el hueso. Ningún paciente relacionó los CF con la
enfermedad cardiovascular. Un 24,4% no se llevaba los CF
cuando salía fuera de casa o estaba con los amigos; eran pa-
cientes más jóvenes a quienes se les habían prescrito un ma-
yor número de comprimidos de CF y que presentaban un
mayor riesgo de no cumplir el objetivo de fósforo (OR =
10,5; IC 95%, –1,8 a 16,4; P <0,001). El porcentaje de pacien-
tes a quienes no les gustaba el CF prescrito fue del 54,5%;
dichos pacientes presentaban un mayor riesgo de tener ni-
veles séricos de fósforo >5,5 mg/dl (OR = 13.3; IC 95%, 1,1-
1,5; P = 0,0001). Paradójicamente, los pacientes que no cum-
plían con el tratamiento demostraban un mejor
conocimiento de su uso (OR = 17,3; IC 95%, 2,2-10,1; P
<0.0001) e importancia (OR = 10,4; IC 95%, 1,5-6,6; P =
0,001). Conclusión: Los pacientes a los que se les habían pres-
crito CF que no les gustaban tenían un peor control de los ni-
veles de fósforo sérico y se les habían recomendado dosis más
altas de los fármacos. El conocimiento de las preferencias de
los pacientes acerca de las medicaciones que se les prescriben
puede ser un factor esencial para conseguir un mayor cum-
plimiento del tratamiento y, por ende, lograr mejores resul-
tados en la consecución de los objetivos terapéuticos.
Palabras clave: Captores del fósforo. Preferencias.
Cumplimiento del tratamiento. Hemodiálisis
INTRODUCTION
Phosphorus (F) control in patients on haemodialysis
constitutes one of the most important issues facing
nephrologists today. Various studies have demonstrated the
difficulty of achieving the goal of F proposed by the
K/DOQI (P <5.5 mg/dL) 1-3 and its impact on morbidity and
mortality.4-6 Additionally, the goals for phosphorus control
are steadily becoming more ambitious and, in fact, figures
are being proposed that come ever closer to normal levels.6
In all likelihood, the lack of compliance with phosphorus
binder (PB) treatment plays an important role in the
difficulty in achieving the objectives of serum phosphorus
level control,7 although the causes for this are not clearly
understood.
PBs present certain characteristics that distinguish them from
other drugs, in particular, they have to be taken with food
and their interference with an individual’s lifestyle and social
habits impacts on the lack of treatment compliance.8 A study
performed on AIDS patients9 showed that the percentage of
patients who did not comply with the treatment increased
considerably when the definition of compliance also took
dietary considerations into account.
Today we have a wide array of PBs10-14 with different
presentations and characteristics. One key concept is to
understand in what measure each of the different types of PB
is adapted to an individual’s habits and behaviour as well as
their expectations, beliefs and preferences.15 The emergence
of increasingly expensive PBs16 makes non-compliance have
a significant economic impact, given that it affects the
efficiency (cost-effectiveness) of treatments, which hinders
achieving clinical effectiveness with the lowest consumption
of resources possible.
The aim of this study was to expand our understanding of
patients’ preferences and beliefs regarding PBs and their
influence on compliance and in achieving therapeutic goals.
PATIENTS AND METHODS
This was an observational transversal study. A total of 121
out of 165 dialysis patients from our unit were included.
Forty-four patients were excluded from the study: 9 patients
were unable to answer the questionnaire due to dementia or
significant hearing loss; 12 patients were not prescribed PBs
and 23 took a single PB, which prevented comparison with
other types of binders.
The 121 patients who were receiving a combination of two
(85 patients) or three PBs (36 patients) answered a
questionnaire specifically related to their preferences
regarding the PBs. The specific questions about PBs referred
to drugs that the patients regularly took (more than 3 months
of treatment). Thirty-six patients took three types of PB:
aluminium hydroxide (Pepsamar®), calcium acetate (Royen®)
and sevelamer (Renagel®). Eighty-five patients took two:
calcium acetate (Royen®) and sevelamer (Renagel®). In
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January 2008, 45 patients who previously had been treated
with high doses of sevelamer had their medication changed
to lanthanum carbonate (Fosrenol®), which allowed this new
medication to be included in the preferences analysis along
with the rest of the PBs after having been used for at least
two months by the patient. Data was collected between
March and April 2008.
Sixty-three percent of the patients were men with a mean age
of 64.8 ± 14.2 years and a mean time on haemodialysis of
154.6. ± 192.4 months (3.74 to 931.5 months). The median
Charlson comorbidity index was 8 (P25-P75: 6-10).
The average number of daily drugs prescribed for this
population was 9.8 ± 3.0 and the average number of daily
tablets was 18.6 ± 7.9, of which 51% were in PB form
(average number of daily PB tablets: 9.5 ±6.0). All patients
had 100% compliance for attending the prescribed dialysis
sessions. The average number of daily tablets for patients
taking calcium acetate (Royen®) was 4.9 ± 2.9; 3.4 ± 1.7 for
aluminium hydroxide (Pepsamar®); 7.1 ± 3.5 for sevelamer
(Renagel®); and 3.0 ± 0.0 for lanthanum carbonate
(Fosrenol®).
Methods for assessing treatment compliance
In general, drug treatment compliance was measured using
the SMAQ compliance questionnaire, which has been
validated for the Spanish AIDS population17 (Table 1). The
answer choices were dichotomous; any response leaning
toward non-compliance was considered as not following
treatment. This questionnaire has been shown to have
sufficient internal consistency (Cronbach’s alpha = 0.75) in
patients infected with HIV, it is easily reproducible (overall
agreement 88.2%; kappa = 0.74)17 and it has been shown to
have sufficient internal consistency in haemodialysis patients
(Cronbach’s alpha for this population = 0.70).8 The specific
compliance with PB treatment was analysed by means of a
specific non-validated questionnaire that asked about PB
treatment compliance, the preferred type of PB and the
reasons why, the least-liked type of PB and the reasons why,
as well as a series of questions about their knowledge of the
usefulness and importance of the drug (“What use have
PBs?”, “Why do you think they are important?”) and about
patient habits (outings, social life).
Measurement of clinical consequences of non-
compliance
The consequences of non-compliance with PB treatment
were estimated indirectly by determining serum phosphorus
levels. Failure to reach the objective occurred when the
average for all monthly phosphorus measurements
performed in the last 6 months exceeded 5.5 mg/dl.
Phosphorus levels were measured using UV spectrometry
(normal range 2.7 to 4.5 mg/dl).
Related variables
We studied possible factors associated with the lack of
compliance, and analysed the following variables that might
affect it:
1. Age.
2. Sex.
3. Time in haemodialysis.
4. Charlson co-morbidity index.18
5. Number of drugs prescribed.
6. Number of tablets per day prescribed.
7. Number of PB tablets per day prescribed.
8. Degree of acceptance of each type of PB. Patients were
questioned about which PB they preferred and which they
liked the least and the reasons why.
9. Knowledge of the usefulness of the drug and its
importance.
10. Influence of habits (outings, social life).
Table 1. SMAQ Compliance questionnaire 
1. Have you ever forgotten to take your medication? Yes      No
2. Do you always take your drugs on time? Yes      No
3. Have you ever stopped taking the drugs because you felt sick? Yes      No
4. Did you forget to take your medication on the weekend? Yes      No
5. How many times did you not take a dose last week? A: 0       
B: 1-2      
C: 3-5      
D: 6-10     
E: more than 10 
6. How many full days since the last visit did you not take the medication? Days: ….
Statistical analysis 
The statistical analysis was performed using SPSS 12.1. We
used the Student’s t-test for the comparison of independent
samples when the data followed a normal distribution. For
those cases in which the data did not, we used the Wilcoxon
test. The qualitative variables were compared using the chi-
squared test and the extent of the association was quantified
using the odds ratio calculation with a confidence interval of
95%. Logistic regression analysis was used in order to
evaluate the possible influence of each of the independent
variables on PB treatment compliance. The dependent
variables were the degree of compliance estimated with the
SMAQ questionnaire, the degree of PB treatment
compliance estimated with the specific questionnaire, and
the average serum phosphorus levels. The independent
variables were age, time on haemodialysis, comorbidity, use
of vitamin D, the number of different types of oral
medication prescribed daily, the number of tablets prescribed
daily and the total number of PB tablets. Statistical
significance was considered to be at P < 0.05.
RESULTS
SMAQ COMPLIANCE QUESTIONNAIRE
According to the SMAQ compliance questionnaire, 40%
(49/121) of the patients assessed were defined as not
following some of the prescribed treatments.
In the 6 months prior to assessing compliance, 14% of
patients studied (17/121) had an average phosphorus level >
5.5 mg/dl and 7.4% (9/121) had >6 mg/dl. The 39.1% of
patients who complied with treatment and 60.9% of those
who did not had serum phosphorus levels > 5.5 mg/dl (OR =
4.8; IC 95%, 1.0-6.6; P = 0.02). The grouP of patients that
did not comply with the treatment according to the SMAQ
questionnaire had an average serum phosphorus level
significantly higher than the group of patients that complied
with the treatment (4.7 ± 0.9 versus 4.4 ± 0.7; P <0.01).
There were no significant differences in the averages for
Kt/V and nPCR between patients with P >5.5 mg/dl (1.45 ±
0.54 and 1.0 ± 0.5 g/dl, respectively) and with P <5.5
mg/dl (1.46 ± 0.54 and 1.1 ± 0.4 g/dl, respectively)
Questionnaire for specific compliance for
phosphorus binders
Some 21.4% of the patients admitted non-compliance
with therapy specifically for PBs. When questioned
about which drug they would not take if they could
choose, 53 patients said they would not stop taking
any of the drugs they were taking (43.9%) and 12
patients said they would stop them all (9.9%). The
group of drugs that the largest percentage of patients
would choose to stop taking were the PBs (20.6%),
followed by Resincalcio® (4.9%) and the hypotensive
drugs (3.3%). The rest (17.5%) corresponded to other
types of drugs in smaller rates.
Patients who specifically did not comply with the PB
treatment had a greater probability of having average
phosphorus readings >5.5 mg/dl (OR = 4.7; IC 95%,
1.07-6.5; P = 0.03). Table 2 shows the factors related
to lack of PB treatment compliance.
The logistic regression analysis showed that none of
the independent variables (age, time on
haemodialysis, comorbidity, use of vitamin D, the
number of different types of oral medication
prescribed daily, the number of tablets prescribed
daily and the total number of PB tablets) were
independently associated with a lack of overall or
specific compliance or with the average levels of
serum phosphorus.
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Table 2. Factors related to treatment compliance or non-compliance of treatment with phosphorus binders (n = 121) 
Compliant with PB Not compliant with PB
(n = 95) (n = 26) p
Age 67.1 ± 14.0 55.2 ± 16.1 0.0001
Time in haemodialysis 151.5 ± 192.6 181.0 ± 198.9 0.50
Charlson co-morbidity index 8.3 ± 2.8 6.0 ± 2.4 0.0001
Number of drugs prescribed per day 9.7 ± 3.0 9.9 ± 3.2 0.81
Number of tablets prescribed per day 18.3 ± 6.8 23.9 ± 8.4 0.005
Number of sevelamer tablets prescribed 6.1 ± 3.9 8.9 ± 4.5 0.007
Number of calcium acetate tablets prescribed 2.0 ± 2.9 5.6 ± 3.4 0.0001
Number of aluminium chelating tablets prescribed 0.5 ± 1.4 2.2 ± 1.9 0.0001
Total number of phosphorus binder 
tablets prescribed 5.4 ± 6.1 14.6 ± 8.2 0.0001
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Preferences, knowledge and habits relating to
phosphorus binders
Some 43.8% (53/121) of the patients had no preferences for
any particular PB and 6.6% (8/121) did not reply to this item
in the survey. Some 54.5% of the patients had a PB
prescribed that they did not like. Table 3 lists the preferences
of the patients for the different types of binders and Table 4
shows the reasons justifying them.
Some 24.4% of patients did not take the medication when
leaving the house or staying with friends, posing a greater
risk of not meeting the goal of P < 5.5 mg/dl (OR = 10.5; IC
95%, 1.8-16.4; P < 0.001). These patients were younger
(59.3 ± 15.8 versus 66.8 ± 14.5; P <0.01) and had a greater
number of daily PB tablets (12.03 ± 7.9 versus 8.7 ± 5.5; P
<0.01)
Patient knowledge and beliefs about the usefulness and
importance of PB are shown in Table 5.
Patients who took a PB that they did not like had a higher
risk of having P readings that were out of control (>5.5
mg/dl) (OR = 13.3; IC 95%, 1.1-1.5; P = 0.0001).
Paradoxically, patients who did not comply with phosphorus
binder treatment had a better understanding of the usefulness
(OR = 17.3; IC 95%, 2.2-10.1; P <0.0001) and importance
of the drug (OR = 10,4; IC 95%, 1.5-6.6; P = 0001).
DISCUSSION
Compliance with CKD treatment in its various aspects is
essential and a large part of its results depend on it. This
study shows a lack of treatment compliance with prescribed
drugs in haemodialysis patients that reaches 40%. In 21% of
cases, there was a specific lack of compliance for PB, which
was associated with higher average serum phosphorus levels.
There are few references that address this issue specifically
and the data reported vary, according to the studies, between
22 and 74% of patients, with a median of 50%.7,19 It is well
known that the lowest compliance levels are observed in
chronic patients in whom there is no discomfort or
immediate risk and in whom the treatment requires a
lifestyle change. Patients with CKD belong to this group of
patients.20
The factors that determine treatment compliance in general
are diverse. Firstly, clear and consistent relationships have
not been found between compliance and socio-demographic
variables or population characteristics7 except in the case of
age (young patients are more likely not to comply). The
profile of a patient that does not comply with PB treatment
was a young patient with lower comorbidity and a greater
number of PB tablets prescribed.
What has been demonstrated is that the complexity and
demands of the treatment regimen influence the lack of
Table 3. Patient prefences with respect to phosphorus binders
Preferred binder Least favourite binder Not defined 
Calcium acetate (Royen®) 29/61 (47.5%) 7/61 (11.4%) 25/61 (40.9%)
Lanthanum carbonate (Fosrenol®) 18/45 (40%) 11/45 (24.4%) 16/45 (35.5%)
Sevelamer (Renagel®) 20/97(20.6%) 42/97 (43.2%) 35/97 (36%)
Aluminium hydroxide (Pepsamar®) 5/27 (18.5%) 11/27 (40.7%) 11/27 (41%)
Table 4. Reasons for justifying not taking various phosphorus binders
Total number Gastric  intolerance Does not like the High number  Bad taste
of patients treated n (%) type of presentation of tablets n (%)
n (%) n (%)
Renagel® 121 8 (6.6%) 16 (13.2%) 33 (27.2%) 0 (0%)
(tablets are 
too large)
Fosrenol® 45 3 (6.6%) 8 (17.7%) 0 (0%) 0 (0%)
(chewable tablets)
Pepsamar® 36 6 (19.4%) 0 (0%) 0 (0%) 8 (22.2%)
Royen® 121 6 (4.9%) 0 (0%) 4 (3.3%) 4 (3.3%)
Total 323 23 (7.1%) 24 (7.4%) 37 (11.4%) 12 (3.7%)
compliance; consequently, the number of daily doses is
inversely proportional to the level of compliance and this, in
turn, is associated with a lower patient quality of life.19
Patients on haemodialysis are prescibed a high number of
daily tablets of which, in our study, more than half are PBs.
Thus, in a previously conducted study by our group,22 with
51 patients with difficulty controlling phosphorus and who
received large doses of sevelamer (more than 9 tablets/day),
changing sevelamer for 3 daily tablets of lanthanum
carbonate helped achieve a better control of serum phosphate
(the percentage of patients with serum phosphate <5.5 mg/dl
increased from 46.9 to 72.5%; p<0.01). The reduction in the
number of tablets may somehow influence patient
compliance with treatment and therefore, produce better
clinical outcomes, as other studies have suggested.19
Interference with daily habits, whether during work hours or
within the context of a patient’s social life, may motivate
some of them to stop taking medication or to take it at the
wrong time. This occurs more frequently with young patients
who have a more active social life. PBs require a very strict
dosage regimen since they must be taken during or
immediately after each meal and, generally, three times a
day, which may be a factor in promoting non-compliance
with treatment with these drugs as opposed to other drugs.8,19
Indeed, a quarter of our patients admitted not taking the
medication when out of the house or when being with
friends. A study performed on AIDS patients23 showed that
the percentage of patients that did not comply with treatment
increased considerably when the definition of compliance
also took dietary considerations into account.
Simplifying the therapy regimen has a certain positive effect
but does not solve the problem of non-compliance since it is
not the only factor involved. Another factor involved, which
was not analysed by our study but should be the subject of
future research, was the influence of the amount of time a
patient had been taking a particular type of binder, since
taking a certain medication for a long period of time may
cause the patient to tire of doing so. In this sense, lanthanum
carbonate may have a certain “advantage” in our study since
it was introduced only two months prior to its initiation. For
example, in our previously-mentioned study on the
conversion from sevelamer to lanthanum carbonate, after 12
months and despite the potential advantages in reducing the
number of tablets, 31% of patients preferred to go back to
sevelamer.20
Additionally, an adequate understanding of the drugs’ actions
may positively influence compliance. Our study
demonstrated the significant lack of knowledge about the
usefulness and importance of PBs. Almost half of the
patients studied did not know what the drugs were for or the
extent of their importance. Not one patient related these
drugs with cardiovascular disease. Adequately conveying the
importance of these drugs is essential and may contribute to
increasing treatment compliance.24 However, knowledge per
se does not ensure compliance. In fact, non-compliant
patients taking PB show, paradoxically, a greater knowledge
of their use and importance, possibly due to dealing with
patients who, faced with the lack of phosphorus control, had
been presssured more towards compliance and had received
more explanations from the doctor. The influence of age
cannot be ruled out, given that younger patients tend to
better understand the indications of chelators.
It is known that a high percentage of patients quit treatment
to avoid side effects, regardless of the clinical relevance
that these may have, which means that drugs that
frequently induce digestive symptoms may constitute a
greater risk of non-compliance. In our population, digestive
intolerance was among the negative side effects of PB,
which include constipation, flatulence, nausea, abdominal
discomfort and dyspepsia. The PB that most digestive
symptoms were attributed to was aluminium hydroxide
(18%), followed by lanthanum carbonate and sevelamer
(6%). Calcium acetate caused the least number of adverse
digestive symptoms (4%).
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Table 5. Responses to questions related to beliefs about the usefulness and importance of phosphorus binders (n = 121)
What is their use? Why are they important?
To control phosphorus 40% 26%
For bones 2% 5%
For cardiovascular disease 0% 0%
Does not know 45% 40%
Does not answer 7% 7%
Misconceptions 6% 2%
Because the doctor says so 0% 11%
Because they are beneficial to health 0% 9%
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More than half of the patients in our population did not like
the PB they were prescribed, and patients who took a PB that
they did not like had a higher risk of having F readings that
were out of control (>5.5 mg/dl). Today we have a wide
array of PBs with different characteristics. The majority of
patients studied received various type of binders and almost
half took two or more types. The PB most positively
regarded among patients that took it was calcium acetate,
followed by lanthanum carbonate, sevelamer and, finally,
aluminium hydroxide. The reasons given by the patients for
negatively rating the PBs were the form, taste, number of
tablets and gastric intolerance. Sevelamer received
complaints about its form for its excessively large tablets and
for requiring a large number of them, which required the
patient to ingest large quantities of water. Some 17.7% of
patients that took lanthanum carbonate did not like the
chewable form and, in fact, some elderly patients had trouble
chewing them. Almost a quarter of the patients that took
aluminium hydroxide reported unpleasant taste.
The first step required for improving therapy compliance is
proper diagnosis of the problem. In some cases, certain
objective parameters, such as the levels of phosphorus, will
clearly indicate that we are faced with a case of non-
compliance. Compliance is often subjectively assessed in
clinical practice. This prevents the identification of many
patients who may be non-compliant, missing the opportunity
to intervene in their behaviour. This also facilitates the
adoption of therapeutic attitudes with a high degree of
empiricism, which in many cases causes an unnecessary
increase in the doses of prescribed drugs. This is justifed by
a theoretical lack of response to treatment even though the
underlying truth is a lack of compliance.
The compliance questionnaires are tools that require few
resources and are affordable and adaptable to the
characteristics of each centre. Research on the use of
compliance questionnaires is a continually advancing issue. It
would be desirable to incorporate new instruments that are
validated for these types of patients. The SMAQ questionnaire
has been validated for HIV+ patients in the Spanish
population but could also be used with CKD patients. In our
study we decided to use a combination of methods to evaluate
compliance: the average levels of serum phosphate and the
responses to the SMAQ questionnaire on compliance with the
medication in general and a specific non-validated
questionnaire in which the patients were asked about their
compliance with PBs. We found that the factors associated
with these three dependent variables were similar, with a
statistically significant association between patients with
average levels of P >5.5 mg/dl in the previous months and the
lack of treatment compliance in accordance with both
questionnaires. These correlations seem to additionally
validate the use of these questionnaires with patients on
haemodialysis. Additionally, the SMAQ showed sufficient
internal consistency in this group of patients (Cronbach’s
alpha = 0.70). Knobel et al17 showed a similar internal
consistency (Cronbach’s alpha = 0.75) among HIV+ patients
as well as a satisfactory reproducibility (88.2% overall
agreement, kappa 0.74). The SMAQ can show its validity for
evaluating treatment compliance in patients on haemodialysis:
it shows adequate levels of sensitivity and specificity when
compared to other more objective measurements; is correlated
with phosphorus levels; is reliable; has sufficient internal
consistency and reproducibility; is easy to apply (takes about 5
minutes); and is inexpensive. 
Knowing the patients’ preferences regarding the prescribed
drugs may be another major factor in achieving good
treatment compliance. It is important for both nephrologists
and the industry to understand these aspects. The
pharmaceutical industry, based on their knowledge of patient
preferences, should try to develop drugs that adjust to these
preferences and develop presentations that are better
tolerated and that pass through the patients as unnoticed as
possible. In addition, as long as there are no medical
contraindications, nephrologists can use in each case those
PBs that each patient prefers or combinations thereof in
order to minimise side effects. Some authors have
suggested25 that a combination of low doses of different
drugs may be a more cost-effective method to ensure
tolerability, efficacy and compliance. In our study, patients
who took binders that they did not like showed poorer
control of serum phosphorus and were the ones prescribed
the highest doses of PB. If lack of compliance is not
explored, it is current practice for the doctor to increase the
prescribed doses, which fails to achieve the objective.19 The
relationship that is established between health care providers
and patients is of utmost importance. Trust, continuity,
accessibility, flexibility and confidentiality are all factors
that favourably influence compliance. Supervision of therapy
compliance by the team that cares for the dialysis patient is a
measure that may contribute favourably to patient
compliance with the prescribed treatment. Probably one of
the most important factors is providing detailed and realistic
information, as well as joint decision making in a framework
of mutual trust (patient-centered model).26
To summarise, short and long-term compliance is the result
of a complex process that is developed through various
stages: acceptance of the diagnosis, perception of the need to
perform correct treatment, the motivation to do so, the
provision and training of skills to carry it out, the capacity of
overcoming the barriers and difficulties that may arise, and
the maintenance of achievements over time. Treatment must
be individualised and adapted to the needs and preferences
of each patient. It is essential to understand the patient’s
daily habits, personal resources and family, and analyse their
understanding of the disease and the degree of awareness
and confidence they have in order to start the treatment. The
assessment of possible risk factors for achieving an optimal
treatment compliance should serve in planning specific
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interventions for each patient, interventions that will
generally be multifaceted and multidisciplinary.27
In conclusion, patients who took PBs that they found
unpleasant, for various reasons, had poorer phosphorus
control despite having a larger quantity of these drugs
prescribed for them, which leads us to believe that the reason
for this lack of control may lie in a lack of treatment
compliance. A greater understanding of the patients’
preferences, the use of different drugs in lower doses, a
better doctor-patient relationship and detailed and accurate
information as part of a joint decision-making process may
be key factors in achieving phosphorus control objectives.28,29
ANNEX. QUESTIONNAIRE ON PHOSPHORUS BINDER
PREFERENCES
1. Which of the medications that you take would you
choose to drop? 
2. Which of the medications that you take for controlling
phosphorus (Pepsamar®, Royen®, Renagel® and
Fosrenol®) do you like the most? Why? 
3. Which of the medications that you take for controlling
phosphorus (Pepsamar®, Royen®, Renagel® and
Fosrenol®) do you like the least? Why? 
4. Of the medcations you are taking for phosphorus,
indicate which ones you like or dislike: 
Pepsamar® LIKE / DISLIKE 
Royen® LIKE / DISLIKE 
Renagel® LIKE / DISLIKE 
Fosrenol® LIKE / DISLIKE 
1. What do you think these medications are for? 
2. Why do you believe these are important to take? 
3. When you leave the house or are with friends, do you
still take the medications? 
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